SRR6013577
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.400
- INTERFERON_GAMMA_RESPONSE+0.310
- KRAS_SIGNALING_UP+0.280
- PROTEIN_SECRETION+0.270
- COAGULATION+0.260
- NOTCH_SIGNALING+0.260
- APICAL_JUNCTION+0.250
- GLYCOLYSIS+0.250
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.470
- CHOLESTEROL_HOMEOSTASIS-0.230
- SPERMATOGENESIS-0.220
- MITOTIC_SPINDLE-0.210
- MYC_TARGETS_V1-0.180
- BILE_ACID_METABOLISM-0.170
- DNA_REPAIR-0.170
- KRAS_SIGNALING_DN-0.140
- ALLOGRAFT_REJECTION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 841ae9cb-ae41-46f9-84ae-03c99fd4e6dd | — | — | 0.788 |
| 2 | R365 | — | — | 0.785 |
| 3 | TCGA-05-4430-01A-02R-1206-07 | — | cohortA1 | 0.757 |
| 4 | MNG439 | — | — | 0.754 |
| 5 | SRR10842367 | — | — | 0.753 |
| 6 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.745 |
| 7 | TCGA-E9-A1NF-01A-11R-A14D-07 | — | C | 0.743 |
| 8 | R66 | — | — | 0.742 |
| 9 | SRR6013590 | — | cohortA1 | 0.741 |
| 10 | TCGA-XF-AAN3-01A-11R-A42T-07 | — | — | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |